一、分论坛介绍

为了进一步提升肿瘤学相关专业领域的学术水平，以创新和学科交融为助力，以国际一流医院及学科建设为目标，开展基础与临床融合，医工交叉的转化与应用，上海交通大学医学院附属仁济医院联合上海市肿瘤研究所承办的“肿瘤基础与临床研究论坛”将邀请相关领域专家齐聚线上，从专业领域内最新前沿发现、热点话题、专业未来发展的机遇与挑战等多个方面与海外青年学者进行探讨和分享。通过构建学术交流与合作平台，推动基础与临床的深度融合，对医院发展提供有力的学术支撑。

 

二、承办单位介绍

上海交通大学医学院附属仁济医院创立于1844年，是上海开埠后第一所西医医院。178年来，医院在传承与弘扬“仁术济世”医学精神的同时，不断创新与超越，发展至今已成为学科门类齐全，集医疗、教学、科研于一体的综合性三级甲等医院。经过十年建设，仁济医院形成了东、西、南、北四个院区及肿瘤所统筹规划、错位发展的一体化格局。

上海市肿瘤研究所成立于1958年，2010年，与仁济医院实现院所合一。2019年整建制划归上海市教育委员会，由上海交通大学医学院和附属仁济医院共同管理。拥有实验室空间约26933平方米，作为癌基因与相关基因国家重点实验室依托单位，研究所设设肿瘤微环境、肿瘤分子病理研究组等20个研究组（室）和动物实验中心、科学研究公共平台、《肿瘤》杂志编辑部等辅助部门。

癌基因与相关基因国家重点实验室成立于1985年，1987年通过国家验收并正式向国内外开放，为国内第一批设立的肿瘤领域国家重点实验室，是我国肿瘤研究的重要基地，瞄准肿瘤研究重大前沿科学问题，目前实验室有固定人员160人，101个课题组。其中正高职称者98人，含中国科学院院士1名，中国工程院院士3人，美国科学院院士/美国艺术与科学院院士/荷兰皇家艺术与科学院院士1人。近三年，实验室在国际学术期刊发表SCI论文600余篇，包括Nature、Science、Cell、Nature Cell Biology等高水平科学期刊。（更多详情）

 

三、论坛主席介绍

论坛主席：陈国强

陈国强，医学博士，上海交通大学医学院教授，中国科学院院士，癌基因与相关基因国家重点实验室主任。

先后多次承担国家重点基础研究（973）计划项目、国家重大科学研究计划项目、国家自然科学基金重点、重大项目和创新群体项目等项目，致力于肿瘤细胞命运决定和肿瘤微环境调控机制研究，取得系列创新性成果，相关研究成果在Cancer Cell，Nat Cell Biol，Nat Chem Biol，Nat Commun，Blood，Leukemia等国际重要学术刊物上发表学术论文200余篇，被他引15000余次。多次获国家自然科学二等奖、中华医学科技一等奖、上海市自然科学一等奖、上海市科技进步一等奖，以及国家教学成果一等奖、上海市教学成果特等奖等，并获何梁何利科学和技术进步奖、卫生部有突出贡献中青年专家、全国先进工作者、新世纪百千万人才工程首批国家级人选、中国青年科技奖、上海市劳动模范、上海十大杰出青年、上海自然科学牡丹奖等荣誉称号。

论坛主席：夏强

夏强，教授、主任医师，博士生导师，上海市领军人才和优秀学科带头人，享受国务院政府特殊津贴。现任上海交通大学医学院附属仁济医院党委书记、肝脏外科主任、上海器官移植与免疫工程技术研究中心主任。致力肝脏肿瘤诊疗及儿童肝移植技术的推广应用，出版发布相关临床诊疗指南。尤其是单中心儿童肝移植年完成量连续八年居世界首位，推动中国儿童肝移植跻身世界先进行列，挽救数千名患儿生命。主持各类课题26项，累计获科研经费4000余万元，以第一或通讯作者发表论文280余篇，其中SCI 130余篇。作为第一完成人获得国家科技进步二等奖一项和省部级科技进步奖一等奖三项。

论坛主席：刘颖斌

刘颖斌，教授，上海市肿瘤研究所所长、上海交通大学医学院附属仁济医院胆胰外科主任、上海市胆道疾病研究所所长、癌基因与相关基因国家重点实验室副主任。刘颖斌教授专注于肝胆胰外科的临床与基础研究工作。在肝胆胰疾病手术治疗领域，作为主要负责人，刘颖斌教授协同彭淑牖教授设计、完善并实践了“捆绑式胰肠吻合术”，此术式显著降低了胰瘘的发生率。刘颖斌教授提出了一套关于安全有效进行肝尾状叶手术的策略和方法，使肝尾状叶切除走出了手术禁区，成为了一个安全有效的手术方式，有效提高肝胆胰外科根治性手术切除率和术后患者的生存率。

刘颖斌教授建立了全国最大多中心胆囊癌单病种数据库，录入胆囊癌病历数过万例。该数据库系统性地描述了我国胆囊癌患者的治疗和生存现状，为胆囊癌的规范化、精准化治疗研究搭建了一个坚实可靠的数据平台。刘教授团队在国际上首次构建胆囊癌体细胞突变谱，明确了ErbB信号通路在胆囊癌发生、发展及免疫微环境中发挥重要作用，提示ErbB信号通路突变的检测和机制研究对胆囊癌的临床治疗策略、药物治疗方法和预后判断都有重要意义。

刘颖斌教授团队的研究成果发表在 Nature Genetics、Journal of Hepatology、Gut、Molecular Cancer、Cancer Letters、Cell Death & Differentiation、Signal Transduction and Targeted Therapy等高水平学术期刊。

四、分论坛议程（待定）

 

五、联系方式

孔老师，电话：68383191   E-mail：renji_hr@renji.com

Basic and Clinical Oncology Forum

1.Forum Introduction

In order to further improve the academic level of oncology-related professional fields, with innovation and disciplinary integration as a base, and with the goal of being a globally acknowledged world-class hospital, carrying out a basic and clinical translational research, the “Basic and Clinical Oncology Forum” hosted by Renji Hospital,Shanghai Jiaotong University School of Medicine and Shanghai Cancer Institute will invite scholars from multiple disciplines to gather online and discuss the latest frontier discoveries in the respective disciplines, current burning topics, opportunities and challenges for the future development of the medical profession, specifically targeting opportunities for young scholars overseas, as well as providing the chance to discuss and exchange. By building a cross-field academic networking and cooperation platform, we aim to promote the deep integration of disciplines, and provide strong academic support for the hospital's multidisciplinary development.

 

2.Organizer Introduction

Renji Hospital, founded in 1844, is the first hospital practicing western medicine in Shanghai. In the last 178 years, Renji was constantly pursuing innovation and transcendence, while inheriting and carrying forward the medical spirit of "benevolence to help the world". It has now become a municipal hospital with a comprehensive list of medical and surgical disciplines, devoted to patient care, medical education and scientific research. In the recent decade, Renji has formed an integrated pattern of logistics and strategy based on four campuses in Eastern, Western, Northern and Southern Shanghai and the Shanghai Cancer Institute.

Shanghai Cancer Institute (SCI) was founded in 1958. In 2010, Shanghai Cancer Institute and Renji Hospital were merged into Cancer Center. Shanghai Cancer Institute has been affiliated to Shanghai Municipal Education Commission in 2019 and now the institute is managed by both Shanghai Jiao Tong University School of Medicine and Renji Hospital.As the host of State Key Laboratory of Oncogenes and Related Genes,

Shanghai Cancer Institute has 26,933 m² of laboratory space, with 20 research groups (labs) such as tumor microenvironment and tumor molecular pathology, as well as research support departments such as animal experiment center, core facilities, and editorial department of Tumor Journal.

The State Key Laboratory of oncogenes and related genes was established in 1985 and has been accessed to home and abroad since 1987. AS the first batch of state key laboratories in the field of cancer and an important base for tumor research in China,it was designed as the platform for the researchers to solve major cutting-edge scientific issues in tumor research . At present, the laboratory has 160 fixed personnel and 101 research groups. Among them, 98 people are titled as senior academic or professional positions, including one academician of the Chinese Academy of Sciences, three academicians of the Chinese Academy of engineering, and one academician of the American Academy of Sciences / the American Academy of Arts and Sciences / the Royal Dutch Academy of Arts and Sciences. In recent three years, more than 600 SCI papers have been published from the laboratory in international academic journals, including high-level scientific journals such as Nature, Science, Cell and Nature cell biology.

 

3.President Introduction

Chen Guoqiang, MD, Professor of Medical School of Shanghai Jiaotong University, academician of Chinese Academy of Sciences, director of State Key Laboratory of oncogenes and related genes.Chen has  undertaken several state-level research projects such as National Key Basic Research (973) program, National Basic Research Program of China, Key ,Major projects and innovative group projects of NSFC. Chen has been devoted to the research on the fate determination of tumor cells and the regulation mechanism of tumor micro-environment from which he has make a series of innovative achievements. Relevant research achievements have been published more than 200 times in Cancer cell, NAT cell biol, NAT Chem Biol, NAT common, Blood, Leukemia and other important international academic journals and cited for more than 15000 times. For his outstanding contribution, he has won the second prize of National Natural Science Award, the first prize of Chinese medical science and technology award, the first prize of Shanghai Natural Science Award, the first prize of Shanghai Science and technology progress award, the first prize of national teaching achievement award and the special prize of Shanghai teaching achievement and titled as the Awardee of Science and Technology Achievement Award by Ho Leung Ho Lee Foundation, middle-aged and young experts with outstanding contributions from the Ministry of health, national advanced workers, the first batch of national candidates of the new century millions of talents project, China Youth Science and technology award Shanghai model worker, Shanghai top ten outstanding youth, Shanghai Natural Science peony award.

Xia Qiang, Professor, Chief Physician, Doctoral supervisor, Head of Renji Hospital, Shanghai Jiao Tong University School of Medicine，director of Liver Surgery Department, director of Shanghai Organ Transplantation and Immune Engineering Technology research center，titled Shanghai Leading Talent and Excellent Subject Leader, awarded by the Special government allowances of the State Council. Prof. Xia has been committed to Diagnosis and treatment of liver tumors. Besides, he has make efforts in the promotion and application of child liver transplantation technology, the formulation of relevant clinical diagnosis and treatment guidelines and was acknowledged as the leader worldwide for eight consecutive years in regard to the number of child liver transplantation completed in a single center, promoting China's child liver transplantation into the world's advanced ranks, ultimately and most importantly: saving thousands of children's lives. In parallel to his clinical engagement, Prof. Xia has taken charge of over 26 various scientific projects with over 40 million RMB of research funds. He has published over 280 papers as first or corresponding author, including over 130 SCI papers. As the project leader, Prof.  Xia won two National Science and Technology Progress Awards and three Provincial and Ministerial Science and Technology Progress Awards.

Prof. Yingbin Liu is the Director of Shanghai Cancer Institute, Director of the Department of Biliary and Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Director of Shanghai Key Laboratory of Biliary Tract Disease Research, and Deputy Director of the State Key Laboratory of Oncogenes and Related Genes.

Prof. Liu focuses on the basic and translational sturdies of hepatobiliary and pancreatic diseases for a goal to improve the optimized surgery rate and the survival phase of patients. As a key contributor, Prof. Liu cooperated with Prof. Peng Shuyou to complete the design, optimization, and completion of a surgery approach namely "bundled pancreatojejunostomy anastomosis", which significantly reduced the incidence of pancreatic fistula. Prof. Liu pioneered a safe and effective strategy for lobe surgery, which proposed the possibility of allowing liver caudate lobe surgery out of the restricted area.

Prof. Liu established the largest multi-center single disease database of gallbladder cancer in China, which covers over 10,000 cases of gallbladder cancer. This contributes a solid and reliable database for the precision medicine of gallbladder cancer. Prof. Liu’s team for the first time constructed the somatic mutation profile of gallbladder cancer. They further approved that the ErbB signaling pathway was involved in tumorigenesis, development, and immune reprogramming of gallbladder cancer, indicating that the detection and underlying mechanisms of ErbB pathway mutations are of great significance for drug discovery, prognosis prediction, and clinical therapy of gallbladder cancer. The research outcomes of the bench and bedside studies from Prof. Liu’s team have been published in multiple high-impact peer-reviewed Journals as Nature Genetics, Journal of Hepatology, Gut, Molecular Cancer, Cancer Letters, Cell Death & Differentiation, Signal Transduction and Targeted Therapy and etc..

 

4.Forum Agenda（TBD）

 

5. CONTACT US

Mr. Kong, Tel: 68383191   E-mail: renji_hr@renji.com